natgillin/translations-raw huggingface dataset:
Menveo contains small amounts of oligosaccharides (a type of sugar) extracted from four groups of the
Menveo sadrži male količine oligosaharida (vrste šećera) ekstrahirane iz četiri grupe bakterije
Menveo is a powder and a solution for injection.
Menveo je prašak i otopina za injekciju.
Menveo is a vaccine that is used for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to a bacterium named Neisseria meningitidis serogroups A, C, W135 and Y, to prevent invasive disease.
Menveo je cjepivo koje se koristi za aktivnu imunizaciju djece (u dobi od 2 i više godine), adolescenata i odraslih s rizikom izlaganja bakteriji pod nazivom Neisseria meningitidis serogrupa A, C, W135 i Y kako bi se spriječila invazivna bolest.
Menveo is given as an intramuscular injection, preferably into the deltoid muscle.
Menveo se daje intramuskularnom injekcijom, po mogućnosti u deltoidni mišić.
Menveo is indicated for active immunization of children (from 2 years of age), adolescents and adults at risk of exposure to Neisseria meningitidis groups A, C, W135 and Y, to prevent invasive disease.
Menveo je indiciran za aktivnu imunizaciju djece (u dobi od 2 i više godina), adolescenata i odraslih s rizikom izloženosti Neisseria meningitidis grupama A, C, W135 i Y kako bi se spriječila invazivna bolest.
Menveo must be prepared for administration by reconstituting powder (in vial) with solution (in vial).
Menveo se mora pripremiti za primjenu rekonstituiranjem praška (u bočici) s otopinom (u bočici).
Menveo must be prepared for administration by reconstituting the powder with the solution.
Menveo se mora pripremiti za primjenu rekonstitucijom praška s otopinom.
Menveo powder and solution for solution for injection
Menveo prašak i otopina za otopinu za injekciju
Menveo should be administered as a single dose (0.5 ml).
Menveo se mora primijeniti kao pojedinačna doza od 0,5 ml.
Menveo was shown to be non-inferior to ACWY-PS vaccine for all four serogroups (A, C, W135 and Y) based on seroresponse, proportions achieving hSBA ≥1:8, and GMTs.
Menveo se pokazao neinferiornim u usporedbi s ACWY-PS cjepivom za sve serogrupe (A, C, W135 i Y) na temelju seroloških odgovora, postigavši rezultate hSBA ≥1:8 i GMTs.
Menveo’s effect could be diminished when administered to individuals who are taking medicines that suppress the immune system.
Učinak cjepiva Menveo može se smanjiti ako se primjenjuje u osoba koje uzimaju lijekove za supresiju imunološkog sustava.
MEPACT 4 mg powder for concentrate for dispersion for infusion Mifamurtide
MEPACT 4 mg prašak za koncentrat za disperziju za infuziju mifamurtid
MEPACT is a white to off-white homogeneous cake or powder for concentrate for dispersion for infusion.
Mepact je bijeli do bjelkasti homogeni kolačić ili prašak za koncentrat za disperziju za infuziju.
MEPACT is supplied in a carton that contains
MEPACT se isporučuje u kutiji koja sadrži
MEPACT is then infused directly into your vein (intravenous) over about one hour.
MEPACT se zatim daje infuzijom u venu (intravenski) u trajanju od jednog sata.
MEPACT must be reconstituted, filtered using the filter provided and further diluted prior to administration.
MEPACT se prije primjene mora rekonstituirati, profiltrirati kroz priloženi filtar i dodatno razrijediti.
MEPACT must be reconstituted, filtered using the filter provided and further diluted using aseptic technique.
MEPACT se mora rekonstituirati, profiltrirati kroz priloženi filtar i dalje razrijediti aseptičkim postupkom.
MEPACT powder for concentrate for dispersion for infusion (vial)
MEPACT prašak za koncentrat za disperziju za infuziju (bočica)
Meperidine
Meperidin
Mepolizumab 100 mg (subcutaneous) N= 69
Mepolizumab 100 mg (supkutano) N= 69
Mepolizumab inhibits the bioactivity of IL-5 with nanomolar potency by blocking the binding of IL-5 to the alpha chain of the IL-5 receptor complex expressed on the eosinophil cell surface, thereby inhibiting IL-5 signalling and reducing the production and survival of eosinophils.
Mepolizumab inhibira biološku aktivnost IL-5 s nanomolarnom potentnosti, tako što blokira vezivanje IL-5 za alfa lanac kompleksa IL-5 receptora koji se eksprimiraju na staničnoj površini eozinofila, te na taj način inhibira signalizaciju putem IL-5 i smanjuje proizvodnju i preživljenje eozinofila.
Mepolizumab pharmacokinetics in adolescent subjects with severe eosinophilic asthma included in the phase 3 studies were consistent with adults (see section 4.2).
Farmakokinetika mepolizumaba u adolescentnih ispitanika s teškom eozinofilnom astmom uključenih u ispitivanja faze 3 bila je u skladu s onom u odraslih (vidjeti dio 4.2).
Mepolizumab vs. placebo
Mepolizumab naspram placeba
Mercaptopurine (used to treat cancer)
merkaptopurin (koristi se za liječenje karcinoma)
Merck KGaA 64271 Darmstadt Germany
Merck KGaA 64271 Darmstadt Njemačka
Merck KGaA, Frankfurter Straße 250 D-64293 Darmstadt Germany
Merck KGaA, Frankfurter Straße 250 D-64293 Darmstadt Njemačka
Merck KGaA, Frankfurter Straße 250, D-64293 Darmstadt, Germany
Merck KGaA, Frankfurter Straße 250, D-64293 Darmstadt, Njemačka
Merck Serono Europe Limited, 56 Marsh Wall,
Merck Serono Europe Limited, 56 Marsh Wall
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, United Kingdom
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, Velika Britanija
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, United Kingdom.
Merck Serono Europe Limited, 56 Marsh Wall, London E14 9TP, Velika Britanija.
Merck Serono S.p.A, Via delle Magnolie 15 (Zona industriale), I-70026 Modugno (Bari), Italy
Merck Serono S.p.A, Via delle Magnolie 15 (Zona industriale), I-70026 Modugno (Bari), Italija
Merck Serono S.p.A. Via delle Magnolie 15 70026 Modugno (Bari) Italy
Merck Serono S.p.A. Via delle Magnolie 15 70026 Modugno (Bari) Italija
Merck Serono S.p.A., Via delle Magnolie 15, 70026 Modugno (Bari), Italy
Merck Serono S.p.A., Via delle Magnolie 15, 70026 Modugno (Bari), Italija
Merck Sharp & Dohme Animal Health S.L. Poligono Industrial El Montalvo I C/Zeppelin 6, Parcela 38
Merck Sharp & Dohme Animal Helath S.L. Poligono Industrial E1 Moltalvo I C/Zeppelin 6, Parcela 38
MERCK SHARP & DOHME ANIMAL HEALTH, S.L.
MERCK SHARP & DOHME ANIMAL HEALTH S.L.
Merck Sharp & Dohme B. V. Waarderweg 39
Merck Sharp & Dohme BV Waarderweg 39,
Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem The Netherlands
Merck Sharp & Dohme B.V. Waarderweg 39 2031 BN Haarlem Nizozemska
Merck Sharp & Dohme B.V., Waarderweg 39, P.O. Box 581, 2003 PC Haarlem, The Netherlands
Merck Sharp & Dohme B.V., Waarderweg 39, P.O. Box 581, 2003 PC Haarlem, Nizozemska
Merck Sharp & Dohme BV Waarderweg 39 2031 BN Haarlem The Netherlands
Merck Sharp & Dohme BV Waarderweg 39 2013 BN Haarlem Nizozemska
Merck Sharp & Dohme BV Waarderweg 39 2031 BN Haarlem The Netherlands
Merck Sharp & Dohme BV Waarderweg 39 2031 BN Haarlem Nizozemska
Merck Sharp & Dohme BV, Waarderweg 39, 2031 BN Haarlem, The Netherlands or
Merck Sharp & Dohme BV, Waarderweg 39, 2031 BN Haarlem, Nizozemska ili
Merck Sharp & Dohme Cyprus Limited
Merck Sharp & Dohme OÜ Tel: +372.614.4200
Merck Sharp & Dohme Cyprus Limited
Merck Sharp & Dohme s.r.o.
Merck Sharp & Dohme Cyprus Limited., Tel: 8007 4433 (+356 99917558)
Merck Sharp & Dohme OÜ, Tel: +372.
Merck Sharp & Dohme d.o.o., Tel: +385 1 66 11 333
Merck Sharp & Dohme d.o.o., Tel: +385 1 66 11
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU Ujedinjeno Kraljevstvo
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp & Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU Ujedinjeno Kraljevstvo
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Ujedinjeno Kraljevstvo
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, United Kingdom.
Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, Velika Britanija.
Merck Sharp & Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp & Dohme Ltd Hertford Road, Hoddesdon Hertfordshire EN11 9BU Velika Britanija
Merck Sharp & Dohme OÜ Tel.: +372 6144 200 msdeesti@merck.com
Bristol-Myers Squibb GmbH & CO.
Merck Sharp & Dohme OÜ Tel.: +372 6144 200 msdeesti@merck.com
Merck Sharp & Dohme OÜ Tel: +372 6144200 msdeesti@merck.com
Merck Sharp & Dohme OÜ, Tel: +372.614.4200
UAB Merck Sharp & Dohme Tel.: +370.5.2780.247
Merck Sharp & Dohme OÜ, Tel: +372.6144 200 Sanofi Pasteur MSD, Tlf: +47.67.50.50.20
Sanofi Pasteur MSD, Tlf: +47.67.50.50.20
Merck Sharp & Dohme Romania S.R.L. Tel: + 40 21 529 2900 msdromania@merck.com
Merck Sharp & Dohme Romania S.R.L. Tel: + 40 21 529 29 00 msdromania@merck.com
Merck Sharp & Dohme Romania S.R.L. Tel: + 4021 529 29 00 msdromania@merck.com
Merck Sharp & Dohme Romania S.R.L. Tel.: + 4021 529 29 00 msdromania@merck.com
Merck Sharp & Dohme s.r.o, Tel.: +420.233.010.111
Merck Sharp & Dohme s.r.o.
Merck Sharp & Dohme, inovativna zdravila d.o.o., Tel: +386.1.520.4201
Merck Sharp & Dohme Romania S.R.L. Tel: + 4021 529 29 00
Merck Sharp & Dohme, inovativna zdravila d.o.o., Tel: +386.1.520.4201
SIA Merck Sharp & Dohme Latvija Tel: +371.67364.224
Merck Sharp & Dohme, Lda Tel: + 351 214 465700 clic@merck.com
Merck Sharp & Dohme, Lda Tel: + 351 214 465 700 clic@merck.com
Merck Sharp & Dohme, Lda.
Merck Sharp & Dohme, Lda
Merck Sharp &Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU United Kingdom
Merck Sharp & Dohme Limited Hertford Road, Hoddesdon Hertfordshire EN11 9BU Ujedinjeno Kraljevstvo
Merck Sharp and Dohme B.V. Waarderweg, 39
Merck Sharp and Dohme B.V. Waarderweg 39
Merck Sharp and Dohme B.V., Waarderweg 39, 2031 BN Haarlem, The Netherlands
Merck Sharp and Dohme B.V., Waarderweg 39, 2031 BN Haarlem, Nizozemska
Merckle GmbH, Ludwig-Merckle-Strasse 3, 89143 Blaubeuren, Germany Teva Pharma B.V., Swensweg 5, 2031 GA Haarlem, The Netherlands
Merckle GmbH, Ludwig-Merckle-Strasse 3, 89143 Blaubeuren,, Njemačka Teva Pharma B.V., Swensweg 5, 2031 GA Haarlem, Nizozemska
Merial Laboratoire Lyon Gerland, 254 rue Marcel Merieux
Merial, Laboratoire Lyon Gerland 254, rue Marcel Mérieux
Merial Laboratoire Porte des Alpes Rue de l'Aviation
Merial, Laboratoire Porte des Alpes Rue de l'Aviation
MERIAL, 29 avenue Tony Garnier, 69007 Lyon, France
MERIAL, 29 avenue Tony Garnier, 69007 Lyon, Francuska
MERIAL, 29 avenue Tony Garnier, 69007 Lyon, France
MERIAL, 29 avenue Tony Garnier, 69007 Lyon, Francuska.
MERIAL, 29 Avenue Tony Garnier, F-69007 Lyon, France
MERIAL, 29 Avenue Tony Garnier, F-69007 Lyon, Franuska
MERIAL, Laboratoire Porte des Alpes, Rue de l'Aviation, F-69800 Saint Priest, France
MERIAL, Laboratoire Porte des Alpes, Rue de l'Aviation, F-69800 Saint Priest, Francuska
MERIAL, Laboratoire Porte des Alpes, Rue de l’Aviation, 69800 Saint Priest, France
MERIAL, Laboratoire Porte des Alpes, Rue de l'Aviation, 69800 Saint Priest, Francuska
MERIAL,Laboratoire Lyon Gerland
MERIAL Laboratoire Lyon Gerland
Merkel cell carcinoma (neuroendocrine
karcinom Merkelovih stanica (neuroendokrini
Merkel cell carcinoma has been reported in patients treated with other TNF-blocking agents (see section 4.8).
U bolesnika liječenih drugim TNF-blokatorima prijavljen je karcinom Merkelovih stanica (vidjeti dio 4.8).
Merkel cell carcinoma*
karcinom Merkelovih stanica
Merus Labs Luxco S.à R.L. 26-28, rue Edward Steichen L-2540 Luxembourg
Merus Labs Luxco S.à R.L. 26-28, rue Edward Steichen L-2540 Luksemburg
MESNA (150 mg/m2/day, IV): days 22-26
MESNA (150 mg/m²/dan, i.v.): dani 22-26
MESNA (360 mg/m2/dose q3h, x 8 doses/day, IV): days 1-5
MESNA (360 mg/m2/doza svaka 3 sata x 8 doza/dan, i.v.): dani 1-5
Mesothelioma
Mezoteliom:
Mesothelioma:
Mezoteliom:
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4).
Meta-analize također konzistentno ukazuju na značajno povećan relativni rizik od tromboembolijskih događaja kod bolesnika s rakom koji primaju rekombinantni humani eritropoetin (vidjeti dio 4.4)
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4).
Meta-analize također konzistentno ukazuju na značajno povećan relativni rizik od tromboembolijskih događaja kod bolesnika s rakom koji primaju rekombinantni humani eritropoetin (vidjeti dio 4.4).
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4).
Metaanaliza je pokazala konzistentan, značajno povećan relativni rizik tromboembolijskog događaja kod bolesnika koji primaju rekombinantni humani eritropoetin (vidjeti dio 4.4).
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4).
Metaanaliza je pokazala konzistentan, značajno povećan relativni rizik tromboemboličkih događaja kod bolesnika koji primaju rekombinantni humani eritropoetin (vidjeti dio 4.4).
Meta-analyses also indicate consistently a significantly increased relative risk of thromboembolic events in cancer patients receiving recombinant human erythropoietin (see section 4.4).
Metaanalize također konzistentno indiciraju na povećan relativni rizik od tromboembolijskih događaja u bolesnika s karcinomom koji primaju rekombinantni humani eritropoetin (vidjeti dio 4.4).
Meta-analysis (2003)
Metaanaliza (2003)
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and
Meta-analiza podataka o ukupnom preživljenju dala je procjenu omjera rizika od 1,06 u korist kontrolnih skupina (95% CI: 1,00; 1,12; 53 ispitivanja i 13933 bolesnika) dok je za bolesnike s rakom na kemoterapiji omjer rizika ukupnog preživljenja iznosio 1,04 (95% CI: 0,97; 1,11; 38 ispitivanja i 10441 bolesnika).
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and
Meta-analiza podataka o ukupnom preživljenju dala je procjenu omjera rizika od 1,06 u korist kontrolnih skupina (95% CI: 1,00; 1,12; 53 ispitivanja i 13933 bolesnika) dok je za bolesnike s rakom na kemoterapiji omjer rizika ukupnog preživljenja iznosio 1.04 (95% CI: 0,97; 1,11; 38 ispitivanja i 10441 bolesnika).
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13,933 patients) and for cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and
Metaanalizom podataka o ukupnom preživljavanju dobivena je procjena točke omjera rizika od 1,06 u korist bolesnika iz kontrolne skupine (interval pouzdanosti 95%: 1,00, 1,12; 53 ispitivanja i 13 933 bolesnika), a omjer rizika u ukupnom preživljavanju bolesnika koji su primali kemoterapiju bio je 1,04 (interval pouzdanosti 95%: 0,97, 1,11; 38 ispitivanja i
Meta-analysis of overall survival data produced a hazard ratio point estimate of 1.06 in favour of controls (95% CI: 1.00, 1.12; 53 trials and 13933 patients) and for the cancer patients receiving chemotherapy, the overall survival hazard ratio was 1.04 (95% CI: 0.97, 1.11; 38 trials and 10,441 patients).
Metaanaliza sveukupnog preživljenja pokazala je procijenjeni omjer rizika od 1,06 u korist kontrola (95% CI: 1,00; 1,12; 53 ispitivanja i 13933 bolesnika) i za bolesnike s rakom koji su primali kemoterapiju, ukupni omjer rizika preživljenja je bio 1,04 (95% CI: 0,97; 1,11; 38 ispitivanja i 10441 bolesnika).
metabolic acidoses, other electrolyte abnormalities, hyponatraemia, fluid overload, hyperuricaemia, hypomagnesaemia, hypokalaemia, hypocalcaemia, appetite decreased, hypercholesterolaemia, hyperlipidaemia, hypertriglyceridaemia, hypophosphataemia
metabolička acidoza, drugi elektrolitski poremećaji, hiponatrijemija, preopterećenje tekućinom, hiperuricemija, hipomagnezijemija, hipokalijemija, hipokalcijemija, smanjeni apetit, hiperkolesterolemija, hiperlipidemija, hipertrigliceridemija, hipofosfatemija
Metabolic acidosis Renal tubular acidosis
metabolička acidoza, bubrežna tubularna acidoza
metabolic acidosis, alkalosis, decreased appetite
metabolička acidoza, alkaloza, smanjenje apetita
Metabolic acidosis1
metabolička acidoza1
Metabolic and transporter based interactions
Interakcije utemeljene na metabolizmu i prijenosnicima
Metabolic bone diseases (including hyperparathyroidism and Paget’s disease of the bone) other than primary osteoporosis or glucorticoid-induced osteoporosis.
Metaboličke bolesti kostiju (uključujući hiperparatireoidizam te Pagetovu bolest kostiju) osim primarne osteoporoze ili osteoporoze izazvane glukokortikoidima.
metabolic disorders caused by the break-down products of dying cancer cells
poremećaji metabolizma uzrokovani razgradnim produktima odumirućih stanica raka
Metabolic interactions are not considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not induce the hepatic cytochrome P450 system in rats (see section 5.2).
Smatra se da nisu vjerojatne metaboličke interakcije budući da ibandronatna kiselina ne inhibira glavne jetrene izoenzime P450 u ljudi i budući da je primijećeno da ne inducira jetreni P450 citokromski sustav u štakora (vidjeti dio 5.2).
Metabolic interactions are not considered likely, since ibandronic acid does not inhibit the major human hepatic P450 isoenzymes and has been shown not to induce the hepatic cytochrome P450 system in rats (see section 5.2).
Smatra se da nisu vjerojatne metaboličke interakcije budući da ibandronatna kiselina ne inhibira glavne jetrene izoenzime P450 u ljudi i budući da je primijećeno da ne inducira jetreni P450 citokromski sustav u štakora (vidjeti dio 5.2).
metabolised via the P450 3A
Cushingov sindrom i supresiju adrenalne funkcije, prijavljeni su u
Metabolisers:
metabolizatora:
metabolising enzymes by St John’s
Noretindron 1,0 mg QD
Metabolism
Poremećaji
Metabolism and
Poremećaji
Metabolism and
Poremećaji krvi i
Metabolism and
Poremećaji metabolizma i
Metabolism and
Poremećaji metabolizma i prehrane
Metabolism and elimination
Metabolizam i eliminacija
Metabolism and nutrition
Poremećaji
Metabolism and nutrition
Poremećaji metabolizma i
Metabolism and nutrition
Poremećaji metabolizma i prehrane
Metabolism and nutrition disorder Rare Loss of /or poor appetite Very rare Dehydration
Poremećaji metabolizma i prehrane Rijetko gubitak /ili smanjenje apetita Vrlo rijetko dehidracija
Metabolism and nutrition disorders
anafilaktička
Metabolism and nutrition disorders
Krvožilni poremećaji
Metabolism and nutrition disorders
metabolizma i prehrane
METABOLISM AND NUTRITION DISORDERS
POREMEĆAJI METABOLIZMA I PREHRANE
Metabolism and nutrition disorders
Poremećaj metabolizm a i prehrane
Metabolism and nutrition disorders
Poremećaji jetre i žuči
Metabolism and nutrition disorders
Poremećaji metabolizm a i prehrane
Metabolism and nutrition disorders
Poremećaji metabolizma i
Metabolism and nutrition disorders
Poremećaji metabolizma i prehrane Manje često:
Metabolism and nutrition disorders
Poremećaji metabolzma i prehrane
Metabolism and nutrition disorders
Poremećaji probavnog sustava
Metabolism and nutrition disorders
Poremećaju metabolizma i prehrane
METABOLISM AND NUTRITION DISORDERS
POREMEČAJI METABOLIZMA I PREHRANE
Metabolism and nutrition disorders
sustava i vezivnog tkiva
Metabolism and nutrition disorders
Često Mučnina
Metabolism and nutrition disorders Common: anorexia, decreased appetite Not known: Dehydration
Poremećaji metabolizma i prehrane Često: anoreksija, smanjenje appetita Nepoznato: dehidracija
Metabolism and nutrition disorders Common: Mild hyperglycaemia* Not known: Insulin resistance*
Poremećaji metabolizma i prehrane Često: blaga hiperglikemija* Nepoznato: inzulinska rezistencija
Metabolism and nutrition disorders Uncommon: Hyperkalaemia
Poremećaji metabolizma i prehrane Manje često: hiperkalemija
Metabolism and nutrition disorders Uncommon: Hypokalaemia
Poremećaji metabolizma i prehrane Manje često: hipokalemija
Metabolism and nutrition disorders Very common: appetite lost
Poremećaji metabolizma i prehrane Vrlo često: gubitak apetita
Metabolism and nutrition disorders:
Poremećaji metabolizma i prehrane
Metabolism and nutrition disorders:
Srčani poremećaji:
Metabolism and nutrition disorders: uncommon: weight decreased, weight gain, anorexia, appetite increased
Poremećaji metabolizma i prehrane: manje često: smanjenje tjelesne težine, povećanje tjelesne težine, anoreksija, pojačan apetit
Metabolism and nutritional disorders
Opći poremećaji i reakcije na mjestu primjene
Metabolism and nutritional disorders
Poremećaji metabolizma i prehrane
Metabolism and nutritional disorders:
Poremećaji metabolizma i prehrane:
metabolism is not dependent
metabolizam ne ovisi o CYP 3A4
Metabolism of Glivec is mainly hepatic, and only 13% of excretion is through the kidneys.
Metabolizam Gliveca odvija se uglavnom preko jetre, dok se samo 13% izlučuje preko bubrega.
Metabolism studies in man have identified the corresponding acid, 1,1-(o,p'-dichlorodiphenyl) acetic acid (o,p’-DDA), as the major circulating metabolite, together with smaller quantities of the 1,1-(o,p'- dichlorodiphenyl)-2,2 dichloroethene (o,p’-DDE) analogue of mitotane.
Ispitivanja metabolizma u čovjeka otkrila su odgovarajuću kiselinu, 1,1-(o,p'-diklordifenil) acetatnu kiselinu (o,p’-DDA), kao glavni cirkulirajući metabolit zajedno s manjim količinama analoga mitotana 1,1-(o,p'-diklordifenil)-2,2 dikloreten (o,p’-DDE).
metabolism)
metabolizma)
metabolism)
procijenjen.
Metabolism: bexarotene metabolites in plasma include 6- and 7-hydroxy-bexarotene and 6- and 7-oxo- bexarotene.
Metabolizam: Metaboliti beksarotena u plazmi uključuju 6- i 7-hidroksi-beksaroten i 6- i 7-okso- beksaroten.
Metabolism: Low blood sugar levels
Metabolizam: niska razina šećera u krvi.
Metabolism: low blood sugar levels.
Metabolizam: niska razina šećera u krvi.
Metabolism: Rasagiline undergoes almost complete biotransformation in the liver prior to excretion.
Metabolizam: Razagilin se gotovo potpuno biotransformira u jetri prije izlučivanja.
Metabolism: studies in humans and in vitro studies using human liver microsomes have demonstrated that atazanavir is principally metabolised by CYP3A4 isozyme to oxygenated metabolites.
Metabolizam: Ispitivanja u ljudi i ispitivanja in vitro na mikrosomima ljudske jetre pokazala su da se atazanavir prvenstveno metabolizira putem izoenzima CYP3A4 do oksigeniranih metabolita.
Metabolism: studies in humans and in vitro studies using human liver microsomes have demonstrated that atazanavir is principally metabolised by CYP3A4 isozyme to oxygenated metabolites.
Metabolizam:: Ispitivanja u ljudi i ispitivanja in vitro na mikrosomima ljudske jetre pokazala su da se atazanavir prvenstveno metabolizira putem izoenzima CYP3A4 do oksigeniranih metabolita.
Metabolite 14-OH clarithromycin
Metabolit 14-OH klaritromicin AUC
Metabolite 14-OH clarithromycin AUC  1.42 (1.16-1.73)
Metabolit 14-OH klaritromicin AUC
Metabolite 14-OH clarithromycin Cmax  1.47 (1.21-1.80)
Metabolit 14-OH klaritromicin Cmax
Metabolite 14-OH clarithromycin Cmin  0 (0.68-1.49)
Metabolit 14-OH klaritromicin Cmin
Metabolite 25-O-desacetylrifabutin
Metabolit 25-O-dezacetilrifabutin
Metabolite 25-O-desacetylrifabutin
Metabolit 25-O-dezacetilrifabutin AUC  1,24 (0,84-1,84)
Metabolite 25-O-desacetylrifabutin AUC  1.24 (0.84-1.84)
Metabolit 25-O-dezacetilrifabutin AUC  1,24 (0,84-1,84)
Metabolite 25-O-desacetylrifabutin Cmin  1.22 (0.86-1.74)
Metabolit 25-O-dezacetilrifabutin Cmin  1,22 (0,86-1,74)
metabolite):
delamanida):